开云app官网登录入口网页版-官方正版

#晚期肾癌#

35篇内容 | 1762人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2183930, encodeId=373221839306e, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a> <a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a> <a href='/topic/show?id=55a6100826cc' target=_blank style='color:#2F92EE;'>#风湿性关节炎#</a> <a href='/topic/show?id=234613893a4' target=_blank style='color:#2F92EE;'>#PD-1#</a>, objectTitle=风暴之后的彩虹，风湿性关节炎肿瘤患者用PD-1后病灶全消失，晚期肾癌治愈的启示！, objectType=article, longId=809766, objectId=86ca809e669a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=86ca809e669a, replyNumber=0, likeNumber=124, createdTime=2024-01-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=86ca809e669a, moduleTitle=风暴之后的彩虹，风湿性关节炎肿瘤患者用PD-1后病灶全消失，晚期肾癌治愈的启示！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=86ca809e669a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1367034, encodeId=7659136e03461, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=手术是肾癌治疗的首选手段！早期、中期、晚期肾癌患者均可获益, objectType=article, longId=735038, objectId=2cdde3503837, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cdde3503837, replyNumber=0, likeNumber=129, createdTime=2022-08-08, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cdde3503837, moduleTitle=手术是肾癌治疗的首选手段！早期、中期、晚期肾癌患者均可获益, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2cdde3503837)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367033, encodeId=0b43136e03379, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Cancer Cell：晚期肾癌抗PD-1反应和耐药性的决定因素, objectType=article, longId=220846, objectId=a40a22084673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a40a22084673, replyNumber=0, likeNumber=92, createdTime=2021-11-24, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a40a22084673, moduleTitle=Cancer Cell：晚期肾癌抗PD-1反应和耐药性的决定因素, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a40a22084673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367032, encodeId=fa09136e032df, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, objectType=article, longId=218568, objectId=c15d218568ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c15d218568ba, replyNumber=0, likeNumber=78, createdTime=2021-10-16, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c15d218568ba, moduleTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c15d218568ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367031, encodeId=c159136e0318c, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Clin Cancer Res：卡瑞珠单抗+法米替尼在晚期肾癌中表现出有效且持久的抗肿瘤活性, objectType=article, longId=216259, objectId=c9c62162592f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9c62162592f, replyNumber=0, likeNumber=78, createdTime=2021-08-26, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9c62162592f, moduleTitle=Clin Cancer Res：卡瑞珠单抗+法米替尼在晚期肾癌中表现出有效且持久的抗肿瘤活性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c9c62162592f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367030, encodeId=ecdc136e030f3, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Eur Urol：3期| 帕唑帕尼用作晚期肾癌患者肾切除术后辅助治疗的疗效, objectType=article, longId=207803, objectId=f3b320e80344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b320e80344, replyNumber=0, likeNumber=70, createdTime=2021-03-03, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b320e80344, moduleTitle=Eur Urol：3期| 帕唑帕尼用作晚期肾癌患者肾切除术后辅助治疗的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f3b320e80344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367029, encodeId=649d136e02996, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, objectType=article, longId=207203, objectId=134820e203ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134820e203ba, replyNumber=0, likeNumber=96, createdTime=2021-02-18, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134820e203ba, moduleTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=134820e203ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367028, encodeId=6644136e02891, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Eur J Cancer：阿昔替尼联合派姆单抗治疗晚期肾癌的长期随访预后良好！, objectType=article, longId=205645, objectId=b54a2056457f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b54a2056457f, replyNumber=0, likeNumber=81, createdTime=2021-01-13, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b54a2056457f, moduleTitle=Eur J Cancer：阿昔替尼联合派姆单抗治疗晚期肾癌的长期随访预后良好！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b54a2056457f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367027, encodeId=ef95136e027ad, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Lancet Oncol：派姆单抗联合阿西替尼治疗初治晚期肾癌的疗效优于单用舒尼替尼（Keynote-426）, objectType=article, longId=205394, objectId=2e7120539485, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e7120539485, replyNumber=0, likeNumber=81, createdTime=2021-01-07, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e7120539485, moduleTitle=Lancet Oncol：派姆单抗联合阿西替尼治疗初治晚期肾癌的疗效优于单用舒尼替尼（Keynote-426）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2e7120539485)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367026, encodeId=fc61136e02691, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, objectType=article, longId=198551, objectId=2cb719855145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb719855145, replyNumber=0, likeNumber=116, createdTime=2020-08-03, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb719855145, moduleTitle=PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2cb719855145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367025, encodeId=ea24136e0250a, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Nat Med：晚期肾癌免疫治疗应答不佳机制被揭密, objectType=article, longId=195590, objectId=3bd719559040, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bd719559040, replyNumber=0, likeNumber=116, createdTime=2020-06-11, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bd719559040, moduleTitle=Nat Med：晚期肾癌免疫治疗应答不佳机制被揭密, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3bd719559040)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367024, encodeId=85a5136e02420, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, objectType=article, longId=192743, objectId=597a192e43e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597a192e43e8, replyNumber=0, likeNumber=106, createdTime=2020-04-24, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597a192e43e8, moduleTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=597a192e43e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367023, encodeId=8b0e136e02364, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=新型靶向药物MK-6482在晚期肾癌中显示出显著疗效, objectType=article, longId=188103, objectId=db3b18810344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db3b18810344, replyNumber=0, likeNumber=107, createdTime=2020-02-16, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db3b18810344, moduleTitle=新型靶向药物MK-6482在晚期肾癌中显示出显著疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=db3b18810344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367022, encodeId=901e136e0227c, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=2019 KCRNC共识：晚期肾癌的管理（更新版）, objectType=article, longId=181242, objectId=0acf1812424b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0acf1812424b, replyNumber=0, likeNumber=56, createdTime=2019-10-16, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0acf1812424b, moduleTitle=2019 KCRNC共识：晚期肾癌的管理（更新版）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0acf1812424b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367021, encodeId=2116136e0214d, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=张海梁教授：晚期肾癌治疗新时代来临，且看免疫加靶向如何出招, objectType=article, longId=180139, objectId=6e1f1801393f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e1f1801393f, replyNumber=0, likeNumber=78, createdTime=2019-09-29, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e1f1801393f, moduleTitle=张海梁教授：晚期肾癌治疗新时代来临，且看免疫加靶向如何出招, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6e1f1801393f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367020, encodeId=a17a136e020a3, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌, objectType=article, longId=178994, objectId=25591e89942d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25591e89942d, replyNumber=0, likeNumber=72, createdTime=2019-09-07, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25591e89942d, moduleTitle=默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25591e89942d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367019, encodeId=3ffe136e019c2, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=Lancet：Atezolizumab联合Bevacizumab一线治疗晚期肾癌, objectType=article, longId=165880, objectId=aef5165880f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aef5165880f7, replyNumber=0, likeNumber=71, createdTime=2019-05-13, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aef5165880f7, moduleTitle=Lancet：Atezolizumab联合Bevacizumab一线治疗晚期肾癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aef5165880f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367018, encodeId=ae46136e018ad, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=K药再拓疆土——细数晚期肾癌靶向治疗现状, objectType=article, longId=165608, objectId=279516560852, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=279516560852, replyNumber=0, likeNumber=70, createdTime=2019-05-09, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=279516560852, moduleTitle=K药再拓疆土——细数晚期肾癌靶向治疗现状, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=279516560852)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367017, encodeId=8857136e017f4, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=NJEM：免疫检查点抑制剂联合阿西替尼，治疗晚期肾癌显疗效, objectType=article, longId=163374, objectId=193a1633e443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=193a1633e443, replyNumber=0, likeNumber=64, createdTime=2019-04-02, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=193a1633e443, moduleTitle=NJEM：免疫检查点抑制剂联合阿西替尼，治疗晚期肾癌显疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=193a1633e443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1367016, encodeId=7143136e0169b, content=<a href='/topic/show?id=8232598e33b' target=_blank style='color:#2F92EE;'>#晚期肾癌#</a>, objectTitle=郭军教授：晚期肾癌治疗再添新力量，基础研究推动临床发展, objectType=article, longId=163148, objectId=a85b1631482c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a85b1631482c, replyNumber=0, likeNumber=67, createdTime=2019-03-30, rootId=0, userName=wujh_7312819, userId=e251248, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a85b1631482c, moduleTitle=郭军教授：晚期肾癌治疗再添新力量，基础研究推动临床发展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a85b1631482c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

晚期肾癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肿瘤# #晚期肾癌# #风湿性关节炎# #PD-1#

风暴之后的彩虹，风湿性关节炎肿瘤患者用PD-1后病灶全消失，晚期肾癌治愈的启示！

2024-01-25发表于陕西省

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

手术是肾癌治疗的首选手段！早期、中期、晚期肾癌患者均可获益

2022-08-08

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Cancer Cell：晚期肾癌抗PD-1反应和耐药性的决定因素

2021-11-24

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者

2021-10-16

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Clin Cancer Res：卡瑞珠单抗+法米替尼在晚期肾癌中表现出有效且持久的抗肿瘤活性

2021-08-26

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Eur Urol：3期| 帕唑帕尼用作晚期肾癌患者肾切除术后辅助治疗的疗效

2021-03-03

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）

2021-02-18

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Eur J Cancer：阿昔替尼联合派姆单抗治疗晚期肾癌的长期随访预后良好！

2021-01-13

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Lancet Oncol：派姆单抗联合阿西替尼治疗初治晚期肾癌的疗效优于单用舒尼替尼（Keynote-426）

2021-01-07

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

PD-L1单抗Bavencio+阿昔替尼：获英国NICE推荐作为晚期肾癌的一线疗法

2020-08-03

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Nat Med：晚期肾癌免疫治疗应答不佳机制被揭密

2020-06-11

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功

2020-04-24

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

新型靶向药物MK-6482在晚期肾癌中显示出显著疗效

2020-02-16

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

2019 KCRNC共识：晚期肾癌的管理（更新版）

2019-10-16

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

张海梁教授：晚期肾癌治疗新时代来临，且看免疫加靶向如何出招

2019-09-29

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

默沙东“免疫+靶向”组合获欧盟批准一线治疗晚期肾癌

2019-09-07

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

Lancet：Atezolizumab联合Bevacizumab一线治疗晚期肾癌

2019-05-13

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

K药再拓疆土——细数晚期肾癌靶向治疗现状

2019-05-09

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

NJEM：免疫检查点抑制剂联合阿西替尼，治疗晚期肾癌显疗效

2019-04-02

wujh_7312819 (审核中...)

前往app查看评论内容

#晚期肾癌#

郭军教授：晚期肾癌治疗再添新力量，基础研究推动临床发展

2019-03-30

科室
- - 订阅+
  - 更多科室
工具
服务